Hiroaki Suga


Hiroaki Suga is a Japanese biochemist and businessman. He is best known for his work on artificial ribozymes and their application in mRNA display.
Suga was awarded the 2023 Wolf Prize in Chemistry, jointly with Chuan He and Jeffery W. Kelly, "for pioneering discoveries that illuminate the functions and pathological dysfunctions of RNA and proteins and for creating strategies to harness the capabilities of these biopolymers in new ways to ameliorate human diseases."

Education

Suga graduated from Okayama University in engineering, and studied at University of Lausanne, where he worked with.
Suga completed his Ph.D. in chemistry at Massachusetts Institute of Technology in 1994 with, working on catalytic antibodies

Career

Scientific

After graduating from MIT with a Ph.D., Suga was a postdoctoral researcher at the Jack W. Szostak lab of Harvard Medical School before starting his independent career at University at Buffalo. Since 2003 he is a faculty member at the University of Tokyo.

Business

Suga is also a founder of PeptiDream Inc. Tokyo, a publicly traded biopharmaceutical start-up company responsible for discovering and developing non-standard peptide therapeutics in addition to addressing unmet medical needs as well as investigating peptide drug conjugates, peptides, and small molecule-based drugs. It is traded publicly on the Tokyo First Stock Exchange Market, which has many partnerships with pharmaceutical companies in worldwide.
Suga is chair of the editorial board at RSC Chemical Biology and associate editor at Angewandte Chemie.

Publications

Suga has published over 250 scientific articles; a small selection is presented here:

Awards